Q2 FY2026 EarningsQ2 FY26 beat consensus across all key financial metrics, with revenue of $12.0M exceeding the $11.6M estimate and a gross margin of 65.1% vs. the 61.5% mean forecast. The company turned GAAP profitable with a net income of $0.25M ($0.01 per share), significantly outperforming the expected loss of $0.91M. Despite a shift in U.S. oncology strategy and the withdrawal of a 510(k) application, management raised full-year gross margin guidance to 62-64%.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: KORU Medical(KRMD) the Revenue is 12.05 M (+18.15%), Beat estimate;the EBIT is 626.99 K (+300.5%), Beat estimate;the EPS is 0.01 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B18.15%
0.01B13.96%
+0.00B4.19%
EBITExceed expectations
0.00B300.53%
-0.00B212.42%
+0.00B512.95%
EPSExceed expectations
0.01--
-0.018--
+0.0280--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf